Shares of GenMark Diagnostics Inc. (NASDAQ:GNMK) have been given a consensus rating of “Buy” by the seven brokerages that are covering the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $12.04.

A number of research analysts have commented on GNMK shares. Cowen and Company upgraded GenMark Diagnostics from a “market perform” rating to an “outperform” rating and set a $17.00 price objective on the stock in a research report on Friday, September 16th. Zacks Investment Research lowered GenMark Diagnostics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 28th. Canaccord Genuity restated a “buy” rating and issued a $13.00 price target on shares of GenMark Diagnostics in a research report on Friday, July 29th. JPMorgan Chase & Co. raised their price target on GenMark Diagnostics from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Friday, July 29th. Finally, Needham & Company LLC started coverage on GenMark Diagnostics in a research report on Friday, June 17th. They issued a “buy” rating and a $13.00 price target on the stock.

In related news, SVP Michael Gleeson sold 7,500 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $9.00, for a total transaction of $67,500.00. Following the sale, the senior vice president now owns 246,934 shares of the company’s stock, valued at approximately $2,222,406. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jennifer Anne Williams sold 24,172 shares of the firm’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $8.63, for a total value of $208,604.36. Following the sale, the senior vice president now directly owns 164,937 shares in the company, valued at approximately $1,423,406.31. The disclosure for this sale can be found here. Corporate insiders own 7.09% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Donaldson Capital Management LLC increased its stake in GenMark Diagnostics by 4.7% in the first quarter. Donaldson Capital Management LLC now owns 66,425 shares of the company’s stock valued at $350,000 after buying an additional 3,010 shares in the last quarter. Geode Capital Management LLC increased its stake in GenMark Diagnostics by 5.8% in the first quarter. Geode Capital Management LLC now owns 286,064 shares of the company’s stock valued at $1,507,000 after buying an additional 15,737 shares in the last quarter. Bogle Investment Management L P DE increased its stake in GenMark Diagnostics by 836.6% in the first quarter. Bogle Investment Management L P DE now owns 136,821 shares of the company’s stock valued at $721,000 after buying an additional 122,213 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in GenMark Diagnostics during the first quarter valued at about $376,000. Finally, Adage Capital Partners GP L.L.C. increased its stake in GenMark Diagnostics by 15.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,575,036 shares of the company’s stock valued at $13,570,000 after buying an additional 350,000 shares in the last quarter.

Shares of GenMark Diagnostics (NASDAQ:GNMK) traded down 4.67% on Thursday, hitting $12.05. The stock had a trading volume of 89,410 shares. The firm’s market cap is $518.07 million. GenMark Diagnostics has a 12-month low of $4.20 and a 12-month high of $13.29. The company’s 50-day moving average price is $10.38 and its 200 day moving average price is $8.41.

GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings data on Thursday, July 28th. The company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.03. The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.62 million. GenMark Diagnostics had a negative return on equity of 108.34% and a negative net margin of 101.78%. The business’s quarterly revenue was up 63.6% compared to the same quarter last year. During the same period last year, the company earned ($0.29) EPS. On average, equities research analysts forecast that GenMark Diagnostics will post ($1.18) earnings per share for the current fiscal year.

About GenMark Diagnostics

GenMark Diagnostics, Inc (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States.

5 Day Chart for NASDAQ:GNMK

Receive News & Stock Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related stocks with our FREE daily email newsletter.